GlaxoSmithKline Consumer Healthcare (GSK Consumer Healthcare)
This sponsor has funded 1 studies across 2 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 15840 | Finalised | EU RMP category 3 | Evaluating the effectiveness of the revised alli® pack information in helping pharmacy staff within the EU supply alli® appropriately (204675) | Yes | No |
PAS by Risk Management Plan (RMP) requirement
GlaxoSmithKline Consumer Healthcare (GSK Consumer Healthcare)
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
GlaxoSmithKline Consumer Healthcare (GSK Consumer Healthcare)
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
GlaxoSmithKline Consumer Healthcare (GSK Consumer Healthcare)
2 Study countries specified are the following:
- Spain
- United Kingdom